Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Neuren Pharmaceuticals Limited ( (AU:NEU) ) has provided an update.
Neuren Pharmaceuticals announced the allowance of a US patent for NNZ-2591, a treatment for Pitt Hopkins syndrome, which currently has no approved therapies. The patent, expiring in April 2040, is a significant step for Neuren, as their Phase 2 trials showed promising improvements in patients. The FDA has granted Orphan Drug and Fast Track designations for NNZ-2591, highlighting its potential impact on the treatment landscape for neurodevelopmental disorders. Neuren is also preparing for a Phase 3 trial of NNZ-2591 for Phelan-McDermid syndrome, further solidifying its position in the industry.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$31.40 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals is focused on developing drug therapies for serious neurological disorders that manifest in early childhood and currently lack effective treatments. The company has received orphan drug designations in the United States to encourage the development of therapies for rare diseases. Neuren’s product DAYBUE™ is approved for Rett syndrome, and they have licensed trofinetide to Acadia Pharmaceuticals for global development and commercialization.
Average Trading Volume: 723,801
Technical Sentiment Signal: Sell
Current Market Cap: A$1.55B
For an in-depth examination of NEU stock, go to TipRanks’ Overview page.